Esther C.W. Breij

机构：Genmab (Netherlands) · ORCID：0000-0002-5368-6849

发表论文 155 篇 · 总被引 3206 次 · h-index 25

代表论文

Cytotoxicity of the CD3×CD20 bispecific antibody epcoritamab in CLL is increased by concurrent BTK or BCL-2 targeting (2023 · Blood Advances · 被引 41)
Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity (2023 · EBioMedicine · 被引 30)
An Antibody–Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy (2023 · Molecular Cancer Therapeutics · 被引 13)
A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade (2025 · Scientific Reports · 被引 1)
739 The combination of HexaBody®-OX40 with PD-(L)1 blockade potentiates agonistic activity in vitro and antitumor activity in vivo (2024 · Regular and Young Investigator Award Abstracts · 被引 1)
731 The combination of an EpCAMx4–1BB bispecific antibody with PD-1 blockade potentiates single-agent effects on T-cell functions and enhances antitumor activity in preclinical studies (2024 · Regular and Young Investigator Award Abstracts · 被引 1)